Spectrum of cognitive impairment in neurocysticercosis Differences according to disease phase


Autoria(s): Rodrigues, C. L.; de Andrade, D. C.; Livramento, J. A.; Machado, L. R.; Abraham, R.; Massaroppe, L.; Lucato, L. T.; Caramelli, P.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

Objectives: Cognitive decline related to neurocysticercosis (NC) remains poorly characterized and underdiagnosed. In a cross-sectional study with a prospective phase, we evaluated cognitive decline in patients with strictly calcified form (C-NC), the epidemiologically largest subgroup of NC, and investigated whether there is a spectrum of cognitive abnormalities in the disease. Methods: Forty treatment-naive patients with C-NC aged 37.6 +/- 11.3 years and fulfilling criteria for definitive C-NC were submitted to a comprehensive cognitive and functional evaluation and were compared with 40 patients with active NC (A-NC) and 40 healthy controls (HC) matched for age and education. Patients with dementia were reassessed after 24 months. Results: Patients with C-NC presented 9.4 +/- 3.1 altered test scores out of the 30 from the cognitive battery when compared to HC. No patient with C-NC had dementia and 10 patients (25%) presented cognitive impairment-no dementia (CIND). The A-NC group had 5 patients (12.5%) with dementia and 11 patients (27.5%) with CIND. On follow-up, 3 out of 5 patients with A-NC with dementia previously still presented cystic lesions with scolex on MRI and still had dementia. One patient died and the remaining patient no longer fulfilled criteria for either dementia or CIND, presenting exclusively calcified lesions on neuroimaging. Conclusions: Independently of its phase, NC leads to a spectrum of cognitive abnormalities, ranging from impairment in a single domain, to CIND and, occasionally, to dementia. These findings are more conspicuous during active vesicular phase and less prominent in calcified stages. Neurology (R) 2012; 78: 861-866

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Brazil

Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Brazil

Janssen-Cilag

Janssen Cilag

Identificador

NEUROLOGY, PHILADELPHIA, v. 78, n. 12, supl., Part 1-2, pp. 861-866, MAR, 2012

0028-3878

http://www.producao.usp.br/handle/BDPI/41665

10.1590/S0004-282X2012000500018

http://dx.doi.org/10.1590/S0004-282X2012000500018

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

PHILADELPHIA

Relação

NEUROLOGY

Direitos

closedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #ALZHEIMERS-DISEASE #BRAZIL #CYSTICERCOSIS #DISORDERS #NEUROLOGY #DEMENTIA #THERAPY #CERAD #CLINICAL NEUROLOGY
Tipo

article

original article

publishedVersion